232 related articles for article (PubMed ID: 19293402)
1. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
[TBL] [Abstract][Full Text] [Related]
2. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
3. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
4. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Aug; 120(9):1888-98. PubMed ID: 22837531
[TBL] [Abstract][Full Text] [Related]
6. Expression of the adaptor protein Lnk in leukemia cells.
Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
[TBL] [Abstract][Full Text] [Related]
7. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
8. LNK mutations and myeloproliferative disorders.
McMullin MF; Cario H
Am J Hematol; 2016 Feb; 91(2):248-51. PubMed ID: 26660394
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
11. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
Gorantla SP; Dechow TN; Grundler R; Illert AL; Zum Büschenfelde CM; Kremer M; Peschel C; Duyster J
Blood; 2010 Nov; 116(22):4600-11. PubMed ID: 20696946
[TBL] [Abstract][Full Text] [Related]
13. Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.
Looi CY; Imanishi M; Takaki S; Sato M; Chiba N; Sasahara Y; Futaki S; Tsuchiya S; Kumaki S
PLoS One; 2011; 6(8):e23640. PubMed ID: 21853157
[TBL] [Abstract][Full Text] [Related]
14. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
Bersenev A; Wu C; Balcerek J; Tong W
J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
[TBL] [Abstract][Full Text] [Related]
15. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
16. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
Simon C; Dondi E; Chaix A; de Sepulveda P; Kubiseski TJ; Varin-Blank N; Velazquez L
Blood; 2008 Nov; 112(10):4039-47. PubMed ID: 18753636
[TBL] [Abstract][Full Text] [Related]
17. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
18. Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling.
Gueller S; Hehn S; Nowak V; Gery S; Serve H; Brandts CH; Koeffler HP
Exp Hematol; 2011 May; 39(5):591-600. PubMed ID: 21310211
[TBL] [Abstract][Full Text] [Related]
19. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.
Lu X; Huang LJ; Lodish HF
J Biol Chem; 2008 Feb; 283(9):5258-66. PubMed ID: 18158285
[TBL] [Abstract][Full Text] [Related]
20. Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.
Louria-Hayon I; Frelin C; Ruston J; Gish G; Jin J; Kofler MM; Lambert JP; Adissu HA; Milyavsky M; Herrington R; Minden MD; Dick JE; Gingras AC; Iscove NN; Pawson T
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20599-604. PubMed ID: 24297922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
